Summary
Only one provided claim set is explicitly evaluated against the supplied CALDOLOR label text (CV thrombotic and serious GI events). Most other claims (adult/OTC dosing, pediatric dosing, intervals, specific contraindication-related patient factors, and safety statements about kidney injury, BP/fluid retention, and severe poisoning) are not supported or contradicted by the limited label excerpts provided.
Category Scores
Accurate Statements
NSAIDs (including CALDOLOR/ibuprofen injection) increase the risk of serious cardiovascular thrombotic events (e.g., myocardial infarction and stroke, which can be fatal) and serious gastrointestinal adverse events (bleeding, ulceration, and perforation, which can be fatal).
Supported by the supplied label excerpts: Warnings and Precautions 5.1 (Cardiovascular Thrombotic Events) and 5.2 (Gastrointestinal Bleeding, Ulceration, and Perforation), with linkage in 6 ADVERSE REACTIONS.
Avoid the use of CALDOLOR in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events; if used, monitor for signs of cardiac ischemia.
Supported by supplied label excerpt under Post-MI Patients in section 5 WARNINGS AND PRECAUTIONS.
Unsupported Statements
For most adults, the typical maximum ibuprofen dose is 3,200 mg total per day.
No dosage maxima for ibuprofen in adults is present in the provided CALDOLOR label excerpts.
For example, 400 mg tablets can be taken up to 8 tablets per day if taken according to OTC directions.
The provided label excerpts do not include OTC tablet strength/dosing instructions or tablet-based maximums.
Adults should take ibuprofen in divided doses throughout the day.
No administration/dosing frequency instructions are present in the provided label excerpts.
Pediatric dosing is weight-based.
No pediatric dosing statements are present in the provided label excerpts.
The maximum daily amount for children should be calculated using the child’s weight and the specific product concentration/strength on the bottle.
No pediatric maximum daily dose calculation guidance is present in the provided label excerpts.
Using an adult maximum dose for a child can be unsafe.
Not supported by the provided label excerpts.
OTC ibuprofen is usually taken every 4 to 6 hours as needed.
Not supported by the provided label excerpts.
Users should follow the exact instructions on the package, especially the “do not exceed” daily limit.
The provided label excerpts do not discuss consumer package directions or a 'do not exceed' daily limit.
Taking more than the maximum daily ibuprofen dose increases the risk of stomach bleeding or ulcers.
The provided label excerpts describe risk with NSAIDs and list risk factors and mitigation strategies, but do not support a specific causal linkage to 'more than the maximum daily dose' in the manner stated.
Taking more than the maximum daily ibuprofen dose increases the risk of kidney injury.
Kidney injury risk is not mentioned in the provided label excerpts.
Taking more than the maximum daily ibuprofen dose increases the risk of higher blood pressure or fluid retention.
Higher blood pressure or fluid retention is not mentioned in the provided label excerpts.
Taking more than the maximum daily ibuprofen dose can cause severe poisoning at high doses.
No overdose/toxicity statement is present in the provided label excerpts.
Stated conditions where people should avoid or ask a clinician first include a history of stomach ulcers or GI bleeding.
The provided label excerpts list GI bleeding risk factors, but do not state 'avoid or ask a clinician first' as phrased, and 'stomach ulcers' is not explicitly used in the provided excerpt text (it refers to prior history of peptic ulcer disease and/or GI bleeding).
Stated conditions where people should avoid or ask a clinician first include a history of kidney disease.
Kidney disease risk factors/avoidance language is not present in the provided label excerpts.
Stated conditions where people should avoid or ask a clinician first include uncontrolled high blood pressure or heart failure.
Uncontrolled high blood pressure and/or heart failure are not mentioned in the provided label excerpts.
Stated conditions where people should avoid or ask a clinician first include use of blood thinners (or certain other medications that increase bleeding risk).
While the GI risk factors list includes concomitant use of oral corticosteroids, aspirin, anticoagulants, or SSRIs, the provided excerpts do not frame this as 'avoid or ask a clinician first include...' for blood thinners generally.
Stated conditions where people should avoid or ask a clinician first include allergy to NSAIDs such as aspirin or naproxen.
NSAID allergy/contraindication language is not present in the provided label excerpts.
People should avoid combining multiple NSAIDs at once, for example ibuprofen plus naproxen.
The label excerpt includes 'avoid more than one NSAID at a time' as part of GI risk mitigation strategies, but the provided excerpts do not include the 'ibuprofen plus naproxen' example; moreover this claim is not fully supported as written if interpreted broadly to apply beyond 'more than one NSAID at a time' context.
Contradictions
Important Omissions
Any CALDOLOR-specific dosing/maximum daily dose limits, pediatric dosing calculations, or OTC tablet strength guidance consistent with the CALDOLOR label.
Importance:
High
Any CALDOLOR label-supported statements for kidney injury, blood pressure/fluid retention, overdose/severe poisoning, and NSAID-allergy avoidance criteria.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The label-supported serious GI/CV risk statement is present, but multiple other dosage and safety claims are not supported by the supplied label excerpts. Several claims appear to rely on general ibuprofen/OTC conventions rather than the provided CALDOLOR label text, which increases risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most dosing, pediatric calculation, interval, overdose/toxicity, and several specific risk-factor/avoidance claims are not supported by the limited CALDOLOR label excerpts provided.
Suggested Improvement
Restrict claims to the supplied label text (e.g., NSAID-associated serious CV thrombotic events and serious GI bleeding/ulceration/perforation; use lowest effective dose/shortest duration; avoid more than one NSAID at a time in the GI risk mitigation context; CABG contraindication; post-MI guidance). Remove or qualify unsupported dosing and non-excerpted safety assertions unless the full label sections are provided.